AIM
AIM ImmunoTech Inc.
Next earnings Aug 12, 2026 · consensus $-0.17 EPS
Last earnings +0.7% on 2026-05-19
$0.31
▼ -12.18%$0.31▼ -96.71%
over 1Y
L $0.23EODHDH $9.56
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-12.2%
1W-18.5%
1M-22.2%
3M-55.4%
YTD-73.7%
1Y-96.7%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Buy
High return on equity (142.7%); but revenue fell -48.2% YoY.
Revenue (FY2025) $88.0K · FY2025
AIM ImmunoTech Inc. shows $88.0K in FY2025 revenue (-48.2% YoY), a -15861.4% net margin, and 142.7% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $135K | $141K | $202K | $170K | $88.0K |
| Gross profit | — | — | — | — | — |
| Operating income | -$18.8M | -$19.9M | -$31.9M | -$19.8M | -$11.7M |
| Net income | -$19.1M | -$19.4M | -$29.0M | -$17.3M | -$14.0M |
| Diluted EPS | — | -$0.40 | -$0.60 | -$30.92 | -$8.62 |
| Net margin | -14168.1% | -13790.8% | -14337.6% | -10188.2% | -15861.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$4.03M
EV / EBITDA—
EV / Sales45.8
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-548.9%
FCF yield-431.6%
Quality & risk
ROIC (est.)—
Free cash flow-$11.0M
Total debt$4.48M
Net cash-$1.49M
Altman Z-Score-113.88 distress
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-88.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗DEF 14APeriod ending 2026-06-252026-06-25open ↗424B3Filing2026-06-24open ↗EFFECTFiling2026-06-23open ↗424B3Filing2026-06-18open ↗S-1Filing2026-06-18open ↗EFFECTFiling2026-06-16open ↗PRE 14APeriod ending 2026-06-152026-06-15open ↗8-KPeriod ending 2026-06-122026-06-15open ↗8-KPeriod ending 2026-06-092026-06-11open ↗8-KPeriod ending 2026-06-092026-06-10open ↗424B5Filing2026-06-10open ↗S-1Filing2026-06-08open ↗
Frequently asked
- Is AIM ImmunoTech Inc. (AIM) a buy?
- AIM currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. High return on equity (142.7%); but revenue fell -48.2% YoY.
- What is AIM ImmunoTech Inc.'s quality score?
- AIM scores 26.235294117647058/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000946644, latest 10-Q filed 2026-05-15) · EODHD · as of 6/23/2026, 12:42:12 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.